•  
  •  
  •  
  •  

2025-10-01 12:46:22

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Reliance Infrastructure Ltd clarifies on media reports related to ED survey under FEMA
  • Sri Lotus Developers & Realty Ltd launches two new projects
  • Tamilnad Mercantile Bank join Hands with Wegofin for Payment Aggregator Business
  • Waaree Energies Ltd commences Commercial Production of 950 MW Solar Module Line Manufacturing facility
  • Bizotic Commercial Ltd receives orders worth Rs. 72.25 crores

Keywords Selected:  MarksansPharma

Stock Report

  • Relonchem Limited receives Marketing Authorization for its products
  • Relonchem Limited receives Marketing Authorization for its products
  • Relonchem Limited receives Marketing Authorization for the product Oxybutynin hydrochloride 2.5mg/5ml Oral Solution
  • Relonchem Ltd receives Marketing Authorization for the product Gabapentin 50 mg/ml oral solution
  • USFDA inspection at manufacturing facility of Marksans Pharma's subsidiary Time-Cap Laboratories, Inc.
  • Marksans Pharma Ltd's manufacturing facility at Verna, Goa approved by Australian TG
  • Relonchem Limited receives Marketing Authorization for the product Baclofen 10 mg Tablets from UK MHRA
  • Relonchem Ltd receives Marketing Authorization for Ibuprofen and Paracetamol tablets
  • Relonchem Limited receives Marketing Authorization from UKMHRA for its products
  • UK Relonchem Ltd, receives Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets
  • Relonchem Limited receives UKMHRA Marketing Authorization for its products
  • Relonchem Ltd receives Marketing Authorisation for the product Levetiracetam Relonchem 100 mg/mL Oral Solution
  • Marksans Pharma Limited updates on USFDA inspection at Verna, Goa manufacturing facility
  • Marksans highest ever quarter revenue at Rs 586 crore grew by 22% YoY, and EBITDA at Rs 133 crore grew by 74 % YoY
  • Marksans Pharma Ltd announces US FDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg
  • Marksans receives USFDA approval for Guaifenesin Extended-Release Tablets (OTC)
  • Marksans announces completion of US FDA Post-marketing Adverse Drug Experience inspection
  • Marksans announces FDA approval of OTC equivalent of Advil Dual Action Tablets
  • Marksans Pharma completes the acquisition from Tevapharm India, expanding the existing manufacturing capacity in India
  • Marksans Pharma Ltd announces US FDA approval for Famotidine Tablets USP, 10 mg and 20 mg
  • Marksans Pharma Ltd Q3FY23 consolidated net profit at Rs. 63.40 crores
  • Marksans Pharma Ltd announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution
  • Marksans Pharma raises Rs. 372.40 crores in equity via conversion of warrants issued to OrbiMed and the Promoter
  • Marksans acquires capacity from Tevapharm India, Plans to double its manufacturing footprint to bolster the growth

Latest Post

  • Reliance Infrastructure Ltd clarifies on media reports related to ED survey under FEMA
  • Sri Lotus Developers & Realty Ltd launches two new projects
  • Tamilnad Mercantile Bank join Hands with Wegofin for Payment Aggregator Business
  • Waaree Energies Ltd commences Commercial Production of 950 MW Solar Module Line Manufacturing facility
  • Bizotic Commercial Ltd receives orders worth Rs. 72.25 crores


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024